GE HealthCare logo

GE HealthCareGEHC

NASDAQ

X-Ray & Radiation Equipment

$81.30-2.17%

AI Multi-Horizon Analysis

Short-term30% confidence
Neutral

No intraday technicals or real-time data available. Price at $69.50 awaits earnings catalyst; balanced risk between positive guidance and further margin/liquidity concerns.

Mid-term50% confidence
Bearish

Margin pressure (op. margin -266 bp QoQ) and liquidity decline dominate near-term fundamentals. Debt/Equity at 0.95 and volatile cash flow add caution despite modest revenue stability.

Long-term40% confidence
Neutral

Longer-term path depends on ability to stabilize margins above 39%/12%, control debt trajectory, and generate consistent FCF. Revenue growth alone insufficient while leverage and liquidity trends remain adverse.

Overall AI View45% confidence
Neutral

Modest revenue growth offset by ongoing margin compression, rising leverage, liquidity contraction, and neutral insider activity. Technical picture limited; near-term price action hinges on earnings reaction and healthcare spending trends.

Detailed AI Fundamental Analysis

Business Snapshot

GE HealthCare Technologies Inc. (GEHC) designs, manufactures, and sells medical imaging, diagnostic, and patient monitoring equipment, with a core focus on X-ray apparatus, tubes, and related irradiation technologies. The company operates as a standalone entity following its spin-off from General Electric in late 2022. With approximately 54,000 employees and a market capitalization of $31.42 billion, GEHC serves hospitals, clinics, and healthcare providers globally. As of the latest close, the common stock trades at $69.50 on NASDAQ.

Financial Trends

Revenue shows modest sequential growth in recent quarters but remains below the full-year 2025 run-rate: Q1 2026 revenue of $5.131B was essentially flat versus Q3 2025 ($5.143B, -0.2%) and up 2.5% from Q2 2025 ($5.007B). Full-year 2025 revenue reached $20.625B.

Gross margin has been gradually compressing: 38.53% in Q1 2026 versus 38.69% in Q3 2025 (-16 bps) and 39.64% in Q2 2025 (-111 bps). Operating margin declined more sharply to 10.04% in Q1 2026 from 12.70% in Q3 2025 (-266 bps) and 13.06% in Q2 2025 (-302 bps). Net margin followed suit, falling to 7.58% in Q1 2026 from 8.67% in Q3 2025 (-109 bps) and 9.71% in Q2 2025 (-213 bps). Full-year 2025 net margin stood at 10.10%.

Balance-sheet leverage is increasing: Long-term debt rose to $10.127B in Q1 2026 from $8.277B in Q3 2025 (+$1.85B or +22.3% over six months) and $8.270B four periods ago. Debt/Equity climbed to 0.95 from 0.83 in Q3 2025. Shareholders’ equity expanded steadily from $9.712B four periods ago to $10.668B in Q1 2026 (+$956M or +9.8%).

Cash from operations has been volatile: $290M in Q1 2026 versus $937M in Q3 2025 (-69%) and $344M in Q2 2025 (-16%). Cash & equivalents dropped sharply from $4.492B at year-end 2025 to $2.261B in Q1 2026 (-$2.231B), driven by heavy investing outflows of -$2.5B in Q1 2026 compared with -$778M in Q3 2025. Free Cash Flow line items are not disclosed in the provided data.

Current ratio improved modestly to 1.22 in Q1 2026 from 1.18 in Q3 2025 but remains below the year-end 2025 peak of 1.37. Working capital stands at $1.897B versus $1.820B in Q3 2025 and $3.396B at year-end 2025.

Financial Health

The most recent quarter (Q1 2026) reflects margin pressure and a material decline in liquidity amid elevated capital deployment. While revenue held relatively steady, the 266 bp contraction in operating margin and 213 bp drop in net margin versus the prior-year comparable quarter signal rising operating expenses relative to sales. The sharp reduction in cash & equivalents (down >50% from year-end 2025) combined with a $1.85B increase in long-term debt over the last two reported quarters has pushed Debt/Equity to 0.95, the highest level in the four-period series. Current ratio of 1.22 remains adequate but is below the December 2025 peak, and working capital has contracted by nearly $1.5B since year-end. Retained earnings continue to grow ($5.654B vs $4.295B four periods ago), supporting underlying equity expansion, yet the trajectory points to increasing leverage and reduced balance-sheet flexibility heading into the remainder of 2026.

Insider Activity

Insider sentiment over the July–October 2026 window is Neutral with a score of -10. There were no open-market purchases (Buys = $0 across three transactions) while insiders executed $914k in sales across 11 transactions, resulting in net selling of $914k. The most recent Form 4 filings on 2026-09-16 reflect three grant or award transactions (totaling 106,973 shares at $0 cost basis) to an executive; these appear to be equity compensation rather than discretionary open-market activity. Overall, the pattern shows modest net selling pressure without aggressive liquidation.

Multi-Timeframe Technical Context

With the active timeframe marked as fundamental and the market closed, real-time 1m–1D candle and indicator data are not available in the current payload. Price sits at $69.50, well below the post-spin highs seen in 2023–2024, suggesting the stock has been in a multi-month consolidation or mild downtrend on the weekly and monthly charts. Absent explicit moving-average, RSI, or volume statistics, technical context is limited to the observation that near-term price action will be driven by reaction to upcoming earnings, macro healthcare spending data, and any further balance-sheet updates.

Bull / Bear Cases

Short-term (hours to days):
Bull case: Any positive pre-announcement commentary or sector rotation into healthcare names could lift the stock from the $69.50 level toward overhead resistance, especially if Q2 guidance implies margin stabilization.
Bear case: Continued evidence of operating-margin compression or further cash burn could trigger selling pressure, potentially retesting recent lows if broader market sentiment weakens.

Long-term (weeks to months):
Bull case: Sustained revenue growth above 2–3% quarterly, successful cost discipline that stabilizes gross and operating margins above 39% and 12% respectively, and deployment of capital into accretive acquisitions could drive equity expansion and support a re-rating of the multiple. Steady growth in retained earnings and a controlled debt trajectory would reinforce this path.
Bear case: Persistent margin erosion, continued rise in long-term debt (already +22% in six months), and liquidity contraction could pressure credit metrics and valuation. If cash from operations remains volatile and investing outflows stay elevated, free-cash-flow generation may disappoint, capping upside and exposing the stock to further de-rating.

Key Levels & Triggers

  • Immediate technical level: $69.50 (current close) — decisive break below may open the mid-$60s; hold and reclaim $72–$74 zone would improve short-term sentiment.
  • Earnings and guidance: Next quarterly report will be watched for margin trajectory versus the 266 bp operating-margin decline seen in Q1 2026.
  • Debt and liquidity triggers: Any further increase in long-term debt or sustained decline in cash below $2.0B could intensify bearish pressure.
  • Insider and institutional flows: Additional open-market selling beyond the $914k seen in recent months would add to negative sentiment.
  • Macro/healthcare policy: Changes in hospital capex budgets or reimbursement rates remain key external catalysts for the X-ray and imaging business.

Financials

From SEC EDGAR · Period 2026-03-31 · Source form 10-Q

Income Statement · last 4 periods

 
2026-03-31
10-Q
2025-12-31
10-K
2025-09-30
10-Q
2025-06-30
10-Q
Revenue$5.13B$20.63B$5.14B$5.01B
Gross Profit$1.98B$8.25B$1.99B$1.99B
Operating Income$515.00M$2.76B$653.00M$654.00M
Net Income$389.00M$2.08B$446.00M$486.00M
EPS (Diluted)$0.85$4.55$0.98$1.06
Gross Margin38.53%39.99%38.69%39.64%
Operating Margin10.04%13.40%12.70%13.06%
Net Margin7.58%10.10%8.67%9.71%

Balance Sheet · last 4 periods

 
2026-03-31
10-Q
2025-12-31
10-Q
2025-09-30
10-Q
2025-06-30
10-Q
Total Assets$37.13B$36.91B$36.13B$35.50B
Total Liabilities$26.23B$26.31B$25.91B$25.55B
Shareholders' Equity$10.67B$10.38B$9.99B$9.71B
Cash & Equivalents$2.26B$4.49B$4.00B$3.74B
Long-term Debt$10.13B$9.49B$8.28B$8.27B
Current Ratio1.221.371.181.16
Debt / Equity0.950.910.830.85

Cash Flow · last 4 periods

 
2026-03-31
10-Q
2025-12-31
10-K
2025-09-30
10-Q
2025-06-30
10-Q
Cash from Operations$290.00M$1.99B$937.00M$344.00M
Cash from Investing-$2.50B-$1.05B-$778.00M-$630.00M
Cash from Financing$21.00M$617.00M$910.00M$1.07B

Income Statement

Revenue
$5.13B
Gross Profit
$1.98B
Operating Income
$515.00M
Net Income
$389.00M
EPS (Basic)
$0.85
EPS (Diluted)
$0.85

Balance Sheet

Total Assets
$37.13B
Total Liabilities
$26.23B
Shareholders' Equity
$10.67B
Cash & Equivalents
$2.26B
Long-term Debt
$10.13B
Shares Outstanding
454.89M

Cash Flow

Cash from Operations
$290.00M
Cash from Investing
-$2.50B
Cash from Financing
$21.00M
Capital Expenditures
$213.00M
Free Cash Flow
$77.00M

Key Ratios

Gross Margin
38.53%
Operating Margin
10.04%
Net Margin
7.58%
Current Ratio
1.22
Debt / Equity
0.95
Free Cash Flow
$77.00M

Insider Activity

1 insider filings (2026-09-16 to 2026-10-16) — sourced directly from SEC Forms 4/5

Buys
$0.00 · 3
Sells
$0.00 · 0
Net
$0.00
Filings Parsed
1
Trade DateInsiderActionSharesPriceValue
2026-09-14Grogan William KBuy62,256$0.00$0.00
2026-09-14Grogan William KBuy12,840$0.00$0.00
2026-09-14Grogan William KBuy31,877$0.00$0.00

Key Stats

$37.51BMarket cap
$89.7752-week high
$66.9552-week low
3,596,266Avg volume (30d)

54,000 employees452.14M shares outstandinglisted 2022-12-15dividend yield 0.20%

Next earnings ~May 5, 2026 · Ex-dividend Apr 2, 2026 · Dividend $0.04 quarterly

About GE HealthCare

GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (15%), and pharmaceutical diagnostics (14%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 11%, and 17%, respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one-third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).

Latest News

Related research

More in Market history

Ready to see the live AI view on GEHC?

Launch a real-time multi-agent room — Claude, GPT, Gemini, DeepSeek, Grok, and Qwen analyzing GEHC side-by-side with live signals.